TABLE 1.
STDD enhancements (%) for compounds 1–5 binding to antibody C3.1 at a 15:1 compound:binding site ratio
Enhancements are normalized to the strongest signal in each spectrum.
| Resonance | STD Enhancement |
||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |
| % | |||||
| Isolated resonances | |||||
| H1A | 73 | 87 | 64 | 100 | 41 |
| H2A | 86 | 76 | 96 | 100 | 64 |
| H3A | 100 | ||||
| H4A | 60 | 86 | 30 | ||
| H4′A | 16 | ||||
| H6A | 18 | ||||
| H6′A | 60 | ||||
| H1B | 55 | 47 | 82 | 60 | 88 |
| H2B | 64 | 44 | 90 | 63 | 88 |
| H4B | 67 | ||||
| H6′B | 92 | ||||
| H1C | 31 | 43 | 38 | 58 | |
| H2C | 49 | 36 | 60 | 54 | |
| H3C | 55 | ||||
| H4C | 20 | ||||
| H4′C | 24 | ||||
| H1D | 40 | ||||
| H2D | 58 | ||||
| Pr 1-CH | 53 | 61 | |||
| Pr 2-CH2 | 29 | 50 | |||
| Pr 3-CH3 | 24 | 50 | |||
| OCH3 | 50 | 67 | 78 | ||
| Overlapping resonances | |||||
| H5AB | 82 | 100 | |||
| H5BC | 100 | ||||
| H5ABC | 64 | ||||
| H5ABCD | 78 | ||||
| H3B,4B,4C | 90 | ||||
| H3A,6B,6C | 78 | ||||
| H5A,6′A,3C | 50 | ||||
| H6AB | 66 | 100 | |||
| H6ABC | 56 | ||||
| H6ABCD | 60 | ||||
| H6′AB | 73 | ||||
| H6′ABC | 53 | ||||
| H6′ABCD | 62 | ||||
| H3AB | 77 | 100 | |||
| H4AB | 100 | 87 | |||
| H6C,6′C,3B,5C | 65 | ||||
| H3B,3C,4B,4C, Pr 1-CH' | 58 | ||||
| H3C,3D,4C,4D, Pr 1-CH' | 55 | ||||